Full professor K.P.M. (Karijn) Suijkerbuijk

Full professor K.P.M. (Karijn) Suijkerbuijk

Full Professor
Full professor K.P.M. (Karijn) Suijkerbuijk
  • Dept of Medical Oncology

Research Programs



Karijn Suijkerbuijk is a translational medical oncologist with special interest in melanoma and immunotherapy. During her PhD, she performed research on tumor epigenetics in breast cancer in the lab of Professor Saraswati Sukumar at the Sidney Kimmel Cancer Center at Johns Hopkins University. Dr. Suijkerbuijk currently participates in multiple phase II and III clinical trials on immune checkpoint inhibitors. She published papers in Oncogene, Annals of Oncology and JNCI, received research grants from KWF and NWO and was awarded an ASCO Merit Award. Her current research focuses on clinical and immunological parameters assoaciated with immune related adverse events during checkpoint inhibition and clinicopathological factors associated with checkpoint inhibitor response.

Side Activities

2023-... Scientific Steering Committee ESMO 2024 (melanoma track chair)

2023-... Chair ESMO Melanoma Faculty

2022-... Member ESMO Real World Data Working Group

2022   Research funding Bristol Myers Squibb

2021-.. Scientific advisory board Maarten vd Weijden foundation

2021-..  ESMO melanoma faculty

2021     Organizer and chair Oncode Melanoma Workshop

2021     Reserach funding TigaTx

2020-.. Data Safety Monitoring Board CHOPIN study (LUMC)

2020    Data Safety Monitoring Board ICRA study (NKI)

2020-..  Member Dutch working group Cancer in Pregnancy

2020-.. Congress organization Immune-oncology symposium

2020  Research funding Novartis

2019-.. Scientific chair Dutch Melanoma Treatment Registry (DMTR)

2019-.. Advisory board member patient society Stichting Melanoom

2019-.. Board member Dutch Melanoma Tumor Focus Group

2018-.. Invited discussant Medtalks

Fellowship and Awards

2007  Research year for residents (UU2007-3977) KWF
2008  Translational grant KWF (UU-2008-4217
2008  AGIKO stipend, ZonMW
2008  ASCO Merit Award

2018 ZonMW goed gebruik geneesmiddelen

Research Output (132)

Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis

van Eijs Mick J.M., ter Linde José J.M., Baars Matthijs J.D., Amini Mojtaba, Laclé Miangela M., Brand Eelco C., Delemarre Eveline M., Drylewicz Julia, Nierkens Stefan, Verheijden Rik J., Oldenburg Bas, Vercoulen Yvonne, Suijkerbuijk Karijn P.M., van Wijk Femke 20 Oct 2023, In: iScience. 26

ESMO Guidance for Reporting Oncology real-World evidence (GROW)

Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen J W G, Suijkerbuijk K P M, Dafni U, Dellaporta T, Vogel A, Prelaj A, Groenwold R H H, Martins H, Stahel R, Bliss J, Kather J, Ribelles N, Perrone F, Hall P S, Dienstmann R, Booth C M, Pentheroudakis G, Delaloge S, Koopman M 10 Oct 2023, In: Annals of oncology : official journal of the European Society for Medical Oncology. 34 , p. 1097-1112 16 p.

Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition

van Eijs Mick J M, Verheijden Rik J, van der Wees Stefanie A, Nierkens Stefan, van Lindert Anne S R, Suijkerbuijk Karijn P M, van Wijk Femke, 4 Oct 2023, In: Cancer Immunology, Immunotherapy. 72 , p. 4049-4064 16 p.

Response to letter Re:Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

van Not Olivier J, Blokx Willeke A M, Wouters Michel W J M, Suijkerbuijk Karijn P M 1 Aug 2023, In: European Journal of Cancer. 191 , p. 112983 1 p.

The use of red flags during the referral chain of patients surgically treated for symptomatic spinal metastases

van Tol Floris R, Kamm Isabelle M L P, Versteeg Anne L, Suijkerbuijk Karijn P M, Verkooijen Helena M, Oner Cumher, Verlaan Jorrit-Jan Jun 2023, In: Neuro-Oncology Practice. 10 , p. 301-306 6 p.

A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

van Not Olivier J, Wind Thijs T, Ismail Rawa K, Bhattacharya Arkajyoti, Jalving Mathilde, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, Boers-Sonderen Marye J, van den Eertwegh Alfonsus J M, de Groot Jan Willem B, Haanen John B, Kapiteijn Ellen, Bloem Manja, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion, van der Veldt Astrid A M, Vreugdenhil Gerard, Wouters Michel W J M, Blokx Willeke A M, Suijkerbuijk Karijn P M, Fehrmann Rudolf S N, Hospers Geke A P 26 May 2023, In: Cancers. 15 12 p.

Immunosuppression for immune-related adverse events during checkpoint inhibition:an intricate balance

Verheijden Rik J, van Eijs Mick J M, May Anne M, van Wijk Femke, Suijkerbuijk Karijn P M 12 May 2023, In: NPJ precision oncology. 7

Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands

van Zeijl Michiel C T, van Breeschoten Jesper, de Wreede Liesbeth C, Wouters Michel W J M, Hilarius Doranne L, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion A, van der Veldt Astrid A M, Vreugdenhil Gerard, Boers-Sonderen Marye J, Suijkerbuijk Karijn P M, Haanen John B A G, van den Eertwegh Alfons J M 28 Apr 2023, In: Human vaccines & immunotherapeutics. 46 , p. 197-204 8 p.

Health-state utilities in long-term advanced melanoma survivors comparable with the general population

Egeler M D, van de Poll-Franse L V, Tissier R, Rogiers A, Boers-Sonderen M J, van den Eertwegh A J, Hospers G A, de Groot J W B, Aarts M J B, Kapiteijn E, Piersma D, Vreugdenhil G, van der Veldt A A, Suijkerbuijk K P M, Neyns B, Janssen K J, Blank C U, Retèl V P, Boekhout A H 20 Apr 2023, In: Quality of Life Research. 32 , p. 2517-2525 9 p.

Added diagnostic value of routinely measured hematology variables in diagnosing immune checkpoint inhibitor mediated toxicity in the emergency department

Niemantsverdriet Michael S A, Vrijsen Bram E L, Visser 't Hooft Therese, Suijkerbuijk Karijn P M, van Solinge Wouter W, Ten Berg Maarten J, Haitjema Saskia 19 Apr 2023, In: Cancer Medicine. 12 , p. 12462-12469 8 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not